Norton Rose Fulbright advises on sale of
Sani-Tech to 3i Group
United States | Press release - Business | August 13, 2020
Norton Rose Fulbright's Los Angeles and Dallas offices advised Sani-Tech West, Inc. in the sale of all of its outstanding stock to an affiliate of 3i Group PLC.
A leading US-based manufacturer, distributor and integrator of bioprocessing systems and components based in Southern California, Sani-Tech develops and manufactures single-use products for leading pharmaceutical and biotech companies.
This expanded portfolio increases 3i Group's product offerings, manufacturing capabilities and expands the combined enterprise's footprint across North America and Europe. Additionally, this combination aims to enhance the ability to serve COVID-19 related vaccine and treatment production for new and existing customers.
3i Group is multinational private equity and venture capital company based in London, United Kingdom focusing on consumer, industrial, technology and healthcare industries.
The deal team was led by Mark Greenfield (Los Angeles), and included Todd Schroeder (Dallas) and Garry Padrta (Los Angeles).
